08:22 AM EST, 11/10/2025 (MT Newswires) -- CRISPR Therapeutics ( CRSP ) reported a Q3 net loss Monday of $1.17 per diluted share, wider than a loss of $1.01 a year earlier.

Three analysts polled by FactSet expected a loss of $1.25.

Total revenue for the quarter ended Sept. 30 was $889,000, up from $602,000 a year earlier.

As of Sept. 30, the company said it had $1.94 billion in cash, cash equivalents and marketable securities.

The company's shares were up more than 5% in recent Monday premarket activity.